The Viewpoint summarizes the role of ERN-EuroBloodNet to improve the overall approach and management of Sickle cell disease patients in EU through key actions developed by the network.
The primary objectives were unveiled during the meeting, each aimed at revolutionizing the approach to R/R AML treatment and ensuring inclusivity and accessibility.
ERN-EuroBloodNet ERN-EuroBloodNet Hôpital St Louis / Université Paris 7 1 avenue Claude Vellefaux 75475 PARIS, France
ERN-EuroBloodNet is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are supported by the European Commission. For more information about the ERNs and the EU health strategy, please visit http://ec.europa.eu/health/ern
You are receiving this newsletter because you are part of the EuroBloodNet inventory of members or because you subscribed. Your data is gathered and processed in line with the General Data Protection Regulation and in accordance with EuroBloodNet Policy. You can unsubscribe any time by clicking below or contacting coordination@eurobloodnet.eu.
